Genomma Lab Internacional B de C : Achieves World Bank / IFC’s Edge (Green Building) Certification

Relación con Inversionistas

T. +52 (55) 5081 0000

Investor.relations@genommalab.com

GENOMMA LAB ACHIEVES WORLD BANK / IFC's

EDGE (GREEN BUILDING) CERTIFICATION

Achieves Important ESG Milestones in the First Half 2022

Mexico City, July 25, 2022 - Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB)

("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, announces that the Company's Industrial Cluster has received EDGE (Excellence in Design for Greater Efficiencies) certification for each of its primary buildings: Pharmaceutical Plant, Personal Care Plant and Distribution Center.

EDGE is a green building standard and a global certification system developed by the International Finance Corporation (IFC), the private arm of the World Bank, that certifies the design and resource efficiency of green buildings. The EDGE label is awarded to buildings that demonstrate resource efficiency of at least 20 percent in energy, water, and embodied energy in materials. The IFC created EDGE to respond to the need for a measurable and credible solution to prove the

Genomma Lab's Industrial Complex is the first pharmaceutical plant in the Western Hemisphere to meet EDGE certification standards.

PERSONAL CARE PLANT EDGE CERTIFICATION:

Genomma's Personal Care Plant design enables 31% in energy savings, 52% in water savings, and 41% less embodied energy in materials versus the local benchmark. 86.64 tons of CO2 will therefore be saved annually.

PHARMA PLANT EDGE ADVANCE CERTIFICATION:

Genomma's OTC Plant design enables 45% in energy savings, 37% in water savings and the uses 42% less embodied energy in materials versus the EDGE benchmark. 33.13 tons of CO2 will therefore be saved annually.

DISTRIBUTION CENTER EDGE CERTIFICATION:

Genomma's Distribution Center design enables 26% in energy savings, 54% in water savings and uses 38% less embodied energy in materials versus the EDGE benchmark. 227.29 tons of CO2 will therefore be saved annually.

"It is a great honor to be EDGE certified and to be the only pharmaceutical plant in the Western Hemisphere to receive the EDGE certification. We are committed to Genomma's ambitious ESG goals throughout our organization," said Genomma Lab CEO Jorge Brake. "That is why one of our top priorities within Genomma's 2025 Sustainability Strategy is sustainable product innovation with minimal environmental impact."

He continued, "We're implementing technologies to treat 100% of the plant's residual water to enable reuse. We're also ensuring that our combined heat and power plant (CHP) provides 50% of the energy used at our Industrial Clusters, simultaneously generating energy from a single fuel source with resulting cleaner energy consumption."

https://inversionistas.genommalab.com

1

Relación con Inversionistas

T. +52 (55) 5081 0000

Investor.relations@genommalab.com

Fernanda Aguilar, Genomma Lab's ESG Director added: "Other noteworthy achievements during the first half of 2022 included:

• Our Industrial Complex has achieved its 'zero waste to landfill' goal
• Secondary packaging of all products sold in Argentina certified for the use of sustainably managed forest resources
• Genomma was included within the "S&P/BMV Mexico ESG Index" for the third consecutive year
• Launch of new environmentally-friendly "Tio Nacho" shampoo, a carbon-neutral packaging that integrates recycled and recyclable materials."

Please click the following link to download our 2025 Sustainability Strategy:

[2025 SUSTAINABILITY STRATEGY]

About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America with an expanding international presence. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low‐cost, highly flexible supply chain operating model. For more information visit: www.genommalab.com

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LABB" (Bloomberg: LABB:MM).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company's related filings with the Bolsa Mexicana de Valores. Any forward-looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

https://inversionistas.genommalab.com

2